378 related articles for article (PubMed ID: 17895472)
21. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
[TBL] [Abstract][Full Text] [Related]
23. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD; Arnold A; Shepherd FA; Dediu M; Ciuleanu TE; Fenton D; Zukin M; Walde D; Laberge F; Vincent MD; Ellis PM; Laurie SA; Ding K; Frymire E; Gauthier I; Leighl NB; Ho C; Noble J; Lee CW; Seymour L
J Clin Oncol; 2010 Jan; 28(1):49-55. PubMed ID: 19917841
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
27. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
28. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
29. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib in lung cancer: clinical developments and future directions.
Blumenschein G
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for non-small-cell lung cancer.
van Meerbeeck JP; Legrand C; van Klaveren RJ; Giaccone G;
Lancet; 2001 Oct; 358(9289):1271-2. PubMed ID: 11675091
[No Abstract] [Full Text] [Related]
32. Designs for randomized phase II clinical trials with two treatment arms.
Hou W; Chang MN; Jung SH; Li Y
Stat Med; 2013 Nov; 32(25):4367-79. PubMed ID: 23630064
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Gridelli C; Rossi A; Mongillo F; Bareschino M; Maione P; Ciardiello F
Clin Lung Cancer; 2007 May; 8(6):396-8. PubMed ID: 17562243
[TBL] [Abstract][Full Text] [Related]
34. Designing exploratory cancer trials using change in tumour size as primary endpoint.
Jaki T; André V; Su TL; Whitehead J
Stat Med; 2013 Jul; 32(15):2544-54. PubMed ID: 23280944
[TBL] [Abstract][Full Text] [Related]
35. One-sample proportion testing procedures for hypothesis of inequality.
Zhong W; Zhong B
J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
[TBL] [Abstract][Full Text] [Related]
36. Seamlessly expanding a randomized phase II trial to phase III.
Inoue LY; Thall PF; Berry DA
Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
[TBL] [Abstract][Full Text] [Related]
37. A sequential phase II/III trial for binary outcomes.
Storer BE
Stat Med; 1990 Mar; 9(3):229-35. PubMed ID: 2160719
[TBL] [Abstract][Full Text] [Related]
38. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
Wason JM; Mander AP; Eisen TG
Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164
[TBL] [Abstract][Full Text] [Related]
39. Optimal two-stage randomized phase II clinical trials.
Logan BR
Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
[TBL] [Abstract][Full Text] [Related]
40. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
DeRose P; Thorpe PE; Gerber DE
Immunotherapy; 2011 Aug; 3(8):933-44. PubMed ID: 21843081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]